Migraine Drugs Market Latest Report By Treatment, Therapeutic Class, Route Of Administration, Country And Forecast To 2025


 San Francisco, 30 Oct 2020: The Report Migraine Drugs Market Analysis Report By Therapeutic Class (Triptans, CGRP-based Therapies, Ditans, Neurotoxins, NSAIDs), By Treatment, By Route of Administration, And Segment Forecasts, 2018 - 2025

The global migraine drugs market size is expected to be valued at USD 7.8 billion by 2025, as per a new report by Grand View Research, Inc., exhibiting an 18.0% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis’ CGRP mAb Aimovig and Teva Pharma’s Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Access Research Report of Migraine Drugs Market @ https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market

Further key findings from the report suggest:

  • Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
  • The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
  • Biohaven’s rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
  • Eli Lilly’s Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
  • Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
  • Drugs with novel targets in early-phase development include AOBiome Therapeutics’ AOB-203 (antibacterial), Winston Pharma’s Dolorac (histamine H1 receptor antagonists), NeuroAxons’ NXN-188 (a combination of NOS inhibitor and a triptan), and Biohaven’s BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Browse more reports of this category by Grand View Research at: https://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global migraine drugs market based on treatment, therapeutic class, route of administration, and country:

Migraine Drugs Treatment Outlook (Revenue, USD Million, 2017 - 2025)

  • Acute / Abortive Treatment
  • Preventive/ Prophylactic Treatment

Migraine Drugs Therapeutic Class Outlook (Revenue, USD Million, 2017 - 2025)

  • Triptans
  • Acetylcholine Inhibitors
  • Ergot Alkaloids
  • NSAIDs
  • Ditans
  • CGRP small molecule antagonists
  • CGRP monoclonal antibodies
  • Others

Migraine Drugs Route of Administration Outlook (Revenue, USD Million, 2017 - 2025)

  • Oral
  • Injectables
  • Others

Migraine Drugs Country Outlook (Revenue, USD Million, 2017 - 2025)

  • The U.S.
  • The U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Japan

Access Press Release of Migraine Drugs Market @ https://www.grandviewresearch.com/press-release/global-migraine-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Asia Pacific PoC Diagnostics Market Growth Opportunities, Industry Analysis And Forecast: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Asia Pacific PoC Diagnostics Market  Analysis And Segment Forecasts To 2020 The Asia Pacific point of care (PoC) diagnostics market is expected to reach USD 5,427.1 million by 2020, according to a new study by Grand View Research, Inc. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of PoC products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expect
Read more

Food Additives Market Size & Share Hit USD 55.53 Billion By 2022 : Grand View Research Inc.

Image
San Francisco, 17 October 2019:   The Report   Global Food Additives Market   Analysis By Product Flavors & Enhancers (Natural, Artificial), Sweeteners (High Intensity, HFCS), Enzymes, Emulsifiers (Mono, Di-Glycerides, Lecithin, Stearoyl Lactylates, Sorbitan Esters), Shelf-life Stabilizers, Fat Replacers (Protein, Starch)] And Segment Forecast To 2022 Global food additives market is expected to reach USD 55.53 billion by 2022, according to a new study by Grand View Research, Inc. Food & beverage industry growth in BRICS and Middle East on account of rising domestic consumption and increasing foreign direct investments is expected to augment market growth. Asia Pacific is expected to be one of the most promising markets on account of growing domestic consumption in China and India owing to population growth and new product launches by food & beverage manufacturers. Availability of raw materials such as sorbitol and lactic acid in China, Indonesia, and Malaysia in light o
Read more

Integration Platform as a Service Market Valuation Is Expected To Exceed USD 2.70 Billion By 2025: Grand View Research Inc.

Image
San Francisco, 18 March 2020 :  The Report   Integration Platform as a Service (IPaaS) Market  Analysis By Integration Type (API, Process, Application, Data), By Services, By Deployment (Cloud, On-Premise, Hybrid) By Region, And Segment Forecasts, 2018 – 2025 The global integration platform as a service (IPaaS) market is expected to reach USD 2.705.8 million by 2025, according to a new report by Grand View Research, Inc. Rising need of advanced systems to improve the process of deploying, developing, and managing enterprise applications globally has been a major factor driving market growth. In addition, recent developments in big data, cloud computing, and Internet of Things (IoT) within organizations’ processes also paved the way for greater development of IPaaS solutions. Integration Platform as a Service is an emerging technology where in the applications, process, data, and application programs are integrated. The integration enables enterprises to reduce the complexity
Read more